Climb Bio’s shares fell 7% in pre-market trading to $14.00 after the company released Phase 1 clinical data for its anti-APRIL monoclonal antibody, CLYM116, in the treatment of IgA nephropathy.
The drug, designed to suppress the APRIL protein, demonstrated near-complete suppression in a single-dose trial of 320 mg. Over a 12-week period, the treatment achieved sustained reductions of 60% to 75% in IgA and Gd-IgA1 levels, with no serious adverse events reported. Climb Bio described the suppression profile as "best-in-class."
The decline in Climb Bio’s stock follows a double-top bearish technical signal identified in early August. The company had also flagged an upcoming research-and-development webcast in its quarterly report. The webcast, held on September 3, 2026, coincided with the publication of the Phase 1 data via an 8-K filing and press release.
Analysts attributed the selloff to a "buy the rumor, sell the news" dynamic, profit-taking, and the absence of immediate catalysts. The next significant data point—initial results from the ongoing Phase 2 NAVIGATE-2 study—is not expected until the first half of 2027.
The broader U.S. market showed mixed performance, with the S&P 500 up 0.3%, the Dow Jones gaining 0.6%, and the Nasdaq rising 0.1%. Wall Street maintains a bullish stance on Climb Bio, with buy recommendations from firms including Truist, Guggenheim, Oppenheimer, and RBC Capital.
Climb Bio’s stock remains well above its 52-week low of $1.54, though it has pulled back from its 52-week high of $18.33.
